Barthelmebs M, Caillette A, Ehrhardt J D, Velly J, Imbs J L
Institut de Pharmacologie, Faculté de Médecine, Université Louis Pasteur, Strasbourg, France.
Kidney Int. 1990 Jun;37(6):1414-22. doi: 10.1038/ki.1990.131.
Gamma-L-glutamyl-L-dopa (or gludopa), a dopamine (DA) prodrug, is selectively metabolized in vivo by the kidney through the sequential action of two renal enzymes, gamma-glutamyl transpeptidase (gamma-GT) and aromatic L-amino acid decarboxylase (AADC). This study was designed to analyze, in vitro, the factors regulating gludopa metabolism and its renal vascular effects. Rat kidneys were perfused in closed circuit with a cell-free perfusion buffer containing 6% bovine serum albumin (BSA). Adding gludopa (final concentration 10(-5) M in the perfusate) led to the release of DA both into urine and perfusate (0.53 +/- 0.21 and 1.38 +/- 0.28 nmol/min/g kidney wt, respectively, during the first 5 min after substrate addition, N = 5, mean +/- SEM). Total DA release (urine plus perfusate) was 73.7 +/- 15.8 nmol/g kidney wt within 30 minutes of recirculation. In non-filtering kidneys, total DA release in the recirculating medium was lower (12.5 +/- 1.4 nmol/g kidney wt, P less than 0.01). Glomerular filtration and access to the gamma-GT on the brush border membrane of proximal tubular cells are therefore required for the maximal conversion rate of gludopa. On filtering kidneys, L-dopa was also converted to DA, but at a higher rate than gludopa (total DA formed within 30 min of recirculation = 131.2 +/- 31.9 nmol/g kidney wt) and this rate was not reduced in non-filtering kidneys (224.2 +/- 41.7 nmol/g kidney wt DA formed within 30 min). Metabolic conversion of L-dopa by AADC is thus preserved in the case of an approach via the basolateral side of the proximal tubular cells. The renal vascular effects of gludopa were studied after vascular tone had been restored by continuous perfusion of PGF2 alpha and after the inhibition of alpha- and beta-adrenoceptors. Gludopa (3.10(-6) to 4.10(-5) M) elicited concentration-dependent renal vasodilatation.(ABSTRACT TRUNCATED AT 250 WORDS)
γ-L-谷氨酰-L-多巴(或谷氨酰多巴)是一种多巴胺(DA)前体药物,在体内通过两种肾脏酶——γ-谷氨酰转肽酶(γ-GT)和芳香族L-氨基酸脱羧酶(AADC)的相继作用被肾脏选择性代谢。本研究旨在体外分析调节谷氨酰多巴代谢及其肾脏血管效应的因素。用含6%牛血清白蛋白(BSA)的无细胞灌注缓冲液在闭路系统中灌注大鼠肾脏。加入谷氨酰多巴(灌注液中的终浓度为10⁻⁵ M)导致DA释放到尿液和灌注液中(在加入底物后的最初5分钟内,分别为0.53±0.21和1.38±0.28 nmol/min/g肾重,N = 5,平均值±标准误)。再循环30分钟内总DA释放量(尿液加灌注液)为73.7±15.8 nmol/g肾重。在无滤过功能的肾脏中,再循环介质中的总DA释放量较低(12.5±1.4 nmol/g肾重,P<0.01)。因此,肾小球滤过以及近端肾小管细胞刷状缘膜上的γ-GT参与对于谷氨酰多巴的最大转化率是必需的。在有滤过功能的肾脏中,L-多巴也可转化为DA,但转化率高于谷氨酰多巴(再循环30分钟内形成的总DA = 131.2±31.9 nmol/g肾重),且在无滤过功能的肾脏中该转化率并未降低(30分钟内形成224.2±41.7 nmol/g肾重的DA)。因此,在通过近端肾小管细胞基底外侧途径时,AADC对L-多巴代谢转化得以保留。在通过持续灌注PGF2α恢复血管张力并抑制α和β肾上腺素能受体后,研究了谷氨酰多巴的肾脏血管效应。谷氨酰多巴(3×10⁻⁶至4×10⁻⁵ M)引起浓度依赖性肾血管舒张。(摘要截短于250字)